Bispecific antibodies are an expanding therapeutic approach with a key challenge in CMC

Over the past months, we have highlighted how CMC strategies shape the success of modern drug development programs. Today we want to discuss how Bispecific Antibodies (bsAbs) represent another excellent example of this series.

Just like with ADC manufacturing, mRNA LNPs, CGTs or CAR-T therapies, as CMC Experts we see how every therapeutic modality introduces their own manufacturing risks, which need to be understood long before they become development bottlenecks. Bispecifics come with their own risks.

 While their ability to simultaneously engage two different targets creates exciting opportunities across oncology and other therapeutic areas, producing these complex molecules consistently, safely, and at commercial scale becomes a critical challenge.

Unlike traditional monoclonal antibodies, bispecific antibodies present additional CMC hurdles due to their asymmetric structures and potential for dimers and mispairing chains during expression. Sophisticated purification approaches, and robust analytical characterization are needed to ensure off target impact does not reduce potency or cause adverse events.

These challenges extend throughout the entire product lifecycle. Cell line selection, upstream and downstream process development, analytical strategy, formulation development, and long-term stability all influence the ability to deliver a reliable product.

The complexity of bispecific manufacturing is changing CMC strategies and CDMO partnerships. Developers must consider manufacturability, process robustness, analytical control, formulation, and technology transfer early, while CDMOs continue to invest in specialized expression, purification, and analytical capabilities. Delaying these decisions can create avoidable development delays, regulatory challenges, and costly rework.

Experienced CMC partners can make the difference between de-risked development and vulnerable strategies. Our Pharmefex team brings expertise spanning antibody development, CMC strategy,   regulatory compliance and CDMO alignment to meet your scientific and regulatory goals.  

As bispecific antibody pipelines continue to grow, the programs most likely to advance efficiently into the clinic and beyond will be those where CMC strategy evolves alongside the molecule itself.

#BispecificAntibodies #Antibodies #Biologics #CMC #DrugDevelopment #Biotechnology #Immunotherapy #Bioprocessing #CDMO #RegulatoryStrategy #Pharmefex #consulting #Dahliaconsulting

Sources

BioProcess International, Process Development, Manufacturing, and Clinical Support for Bispecific Antibodies: Chemistry, Manufacturing, and Controls Considerationshttps://www.bioprocessintl.com/process-development/process-development-manufacturing-and-clinical-support-for-bispecific-antibodies-chemistry-manufacturing-and-controls-considerations

WHO, Guideline on the Production and Quality Control of Monoclonal Antibodies and Related Products (draft)https://cdn.who.int/media/docs/default-source/biologicals/mabs-manufacture-guideline-draft-for-1st-public-comment.pdf

Fortune Business Insights, Bispecific Antibody Market Analysis (2026)

WuXi Biologics / Contract Pharma industry reports and commentary on bispecific manufacturing capacity and CMC trends (2026)

PatSnap, Bispecific Antibody Patent Landscape Analysis (April 2026)

Oxford Academic, publications on bispecific antibody engineering and manufacturing challenges (2024)